Akebia Therapeutics Inc (AKBA)
1.86
-0.06
(-3.12%)
USD |
NASDAQ |
Nov 14, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Free Cash Flow: -38.53M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -38.53M |
| June 30, 2024 | -39.00M |
| March 31, 2024 | -25.28M |
| December 31, 2023 | -23.38M |
| September 30, 2023 | -75.76M |
| June 30, 2023 | -34.78M |
| March 31, 2023 | -69.07M |
| December 31, 2022 | -73.27M |
| September 30, 2022 | -81.40M |
| June 30, 2022 | -171.47M |
| March 31, 2022 | -203.95M |
| December 31, 2021 | -253.02M |
| September 30, 2021 | -221.32M |
| June 30, 2021 | -192.24M |
| March 31, 2021 | -91.92M |
| December 31, 2020 | -110.70M |
| September 30, 2020 | -171.96M |
| June 30, 2020 | -136.31M |
| March 31, 2020 | -213.83M |
| December 31, 2019 | -264.10M |
| September 30, 2019 | -246.27M |
| June 30, 2019 | -267.50M |
| Date | Value |
|---|---|
| March 31, 2019 | -218.33M |
| December 31, 2018 | -99.10M |
| September 30, 2018 | -41.40M |
| June 30, 2018 | -83.84M |
| March 31, 2018 | -68.45M |
| December 31, 2017 | -57.78M |
| September 30, 2017 | 54.67M |
| June 30, 2017 | 80.38M |
| March 31, 2017 | 27.96M |
| December 31, 2016 | 55.24M |
| September 30, 2016 | -63.36M |
| June 30, 2016 | -43.01M |
| March 31, 2016 | -26.95M |
| December 31, 2015 | -52.82M |
| September 30, 2015 | -39.06M |
| June 30, 2015 | -35.56M |
| March 31, 2015 | -30.11M |
| December 31, 2014 | -27.71M |
| September 30, 2014 | -23.41M |
| June 30, 2014 | -20.71M |
| March 31, 2014 | -15.81M |
| December 31, 2013 | -11.33M |
Free Cash Flow Range, Past 5 Years
-264.10M
Minimum
Dec 2019
-23.38M
Maximum
Dec 2023
-124.56M
Average
-101.31M
Median
Free Cash Flow Benchmarks
| Corcept Therapeutics Inc | 142.60M |
| Bioventus Inc | 29.05M |
| Eli Lilly and Co | -2.275B |
| NovaBay Pharmaceuticals Inc | -4.812M |
| Palatin Technologies Inc | -31.50M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -6.695M |
| Cash from Investing (Quarterly) | -0.002M |
| Cash from Financing (Quarterly) | 1.223M |
| Free Cash Flow Per Share (Quarterly) | -0.0318 |
| Free Cash Flow to Equity (Quarterly) | -7.021M |
| Free Cash Flow Yield | -10.17% |